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ABSTRACT
Aims/Introduction: Bacterial septicemia has diverse clinical symptoms including severe
hypoglycemia. However, sepsis-induced hypoglycemia has not yet been examined in
detail. The aim of the present study was to investigate the mechanisms underlying hypo-
glycemia in sepsis.
Materials and Methods: We induced endotoxin shock in rats using lipopolysaccharide
(LPS). After an intraperitoneal injection of LPS, we measured gluconeogenesis using the
pyruvate tolerance test. The effects of LPS on glucose metabolism were investigated in
perfused livers and isolated hepatocytes. Furthermore, its effects on the production of
inflammatory cytokines were examined in isolated splenocytes. The interaction between
splenocytes and hepatocytes in response to LPS was investigated in vitro using a co-cul-
ture of splenocytes and hepatocytes.
Results: In the pyruvate tolerance test, the pretreatment with LPS decreased gluconeo-
genesis. The in vivo pretreatment of rats with LPS did not inhibit glucose production in
perfused livers. The in vitro treatment of isolated hepatocytes with LPS did not decrease
hepatic gluconeogenesis. Although LPS increased the production of inflammatory cytoki-
nes (tumor necrosis factor-a, interferon-c, interleukin-1b, interleukin-6 and interleukin-10)
and nitric oxide in isolated splenocytes, only nitric oxide significantly inhibited gluconeo-
genesis in isolated hepatocytes. When splenocytes and hepatocytes were co-cultured in
medium containing LPS, the messenger ribonucleic acid expression of glucose-6-phospha-
tase in hepatocytes was suppressed.
Conclusions: LPS reduced hepatic gluconeogenesis, at least in part, by stimulating the
production of nitric oxide in splenocytes. This effect could contribute to the mechanisms
responsible for septicemia-induced hypoglycemia.
INTRODUCTION
Sepsis is a systemic response caused by pathogenic microorgan-
isms, and is accompanied by a number of clinical symptoms1.
These symptoms include endotoxin shock caused by
lipopolysaccharide (LPS), a component of the outer membrane
of Gram-negative bacteria. Septicemia causes not only hyper-
glycemia, but also hypoglycemia. Although the incidence of
hypoglycemia is markedly lower than that of hyperglycemia,
the mechanisms underlying hypoglycemia in sepsis must be
considered. Endotoxic hypoglycemia plays an important role in
predicting the severity and prognosis of sepsis2.
Several studies examined the mechanisms responsible for the
development of hypoglycemia in animals or humans with sep-
sis. LPS was shown to increase insulin sensitivity3, and inhibit
hepatic gluconeogenesis4,5. To the best of our knowledge, the
mechanism underlying hypoglycemia in sepsis has not yet been
elucidated. LPS stimulates immune cells and increases the secre-
tion of inﬂammatory cytokines, such as tumor necrosis factor-a
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(TNF-a). It is also a representative ligand of Toll-like recep-
tor 4, which is predominantly expressed in macrophages and
dendritic cells6. Toll-like receptor 4 is crucially involved in
immune responses, which are the ﬁrst line of defense against
infectious diseases7.
Phosphoenolpyruvate carboxykinase (PEPCK) is an enzyme
that catalyzes the rate-limiting step of gluconeogenesis, and glu-
cagon increases its activity8. TNF-a, a protein induced by LPS,
inhibits glucagon-stimulated PEPCK gene expression and gluco-
neogenesis9,10. LPS also increases hepatic insulin sensitivity3,
and accordingly, might exert hypoglycemic effects. In contrast,
Sugita et al11 previously reported that hyperglycemia and insu-
lin resistance were induced by LPS. Thus, glucose metabolism
during septic shock has not yet been examined in detail.
Macrophages activated by LPS generate nitric oxide (NO), a
highly reactive molecule with a number of important biological
actions. NO is synthesized by three different NO synthase
(NOS) isoforms: inducible NOS (iNOS), endothelial NOS and
neuronal NOS. iNOS is primarily expressed in immunocytes,
and produces large quantities of NO when stimulated by LPS,
leading to marked increases in plasma NO concentrations. Hor-
ton et al.12 showed that the addition of NO donors to incuba-
tion medium inhibited gluconeogenesis in isolated hepatocytes,
which supports increases in plasma NO levels in vivo also
inhibiting hepatic gluconeogenesis.
We herein investigated the mechanisms underlying glucose
dyshomeostasis in sepsis, and clariﬁed whether LPS inhibits
hepatic gluconeogenesis. Our results showed that LPS failed to
exert any direct effects on gluconeogenesis in isolated hepato-
cytes or perfused livers. Furthermore, using isolated splenocytes,
we measured the production of representative inﬂammatory
cytokines (TNF-a, interferon [IFN]-c, interleukin [IL]-1b, IL-6
and IL-10) and NO after stimulation with LPS. Our results
showed that LPS increased the secretion of TNF-a, IFN-c, IL-
1b, IL-10 and NO from splenocytes. We measured glucose pro-
duction in isolated hepatocytes after stimulations with TNF-a,
IFN-c, IL-1b, IL-6, IL-10 and NO, and found that gluconeoge-
nesis in primary hepatocytes was suppressed by the addition of
sodium nitroprusside (SNP), a NO donor, but not by TNF-a,
IFN-c, IL-1b, IL-6 or IL-10. Our results showed that LPS sup-
pressed the messenger ribonucleic acid (mRNA) expression
levels of G6Pase, a master regulator of glucose production, in
hepatocytes co-cultured with splenocytes. Therefore, LPS might
inhibit hepatic gluconeogenesis, at least partly, by increasing the
release of NO from the spleen, and does not appear to act
directly on the liver.
METHODS
Animals
Male Wistar rats, weighing approximately 180 g (8 weeks-of-
age), were purchased from Japan SLC, Inc. (Hamamatsu, Japan)
and maintained in a temperature-controlled (25 – 1°C) envi-
ronment with a 12-h light/dark cycle. Rats had free access to
standard laboratory chow and water, and were maintained and
used in accordance with the Guidelines for Animal Experi-
ments of Tezukayama Gakuin University.
Effects of LPS on blood glucose
Blood glucose levels were measured, followed by an intraperi-
toneal injection of saline (control) or LPS from Escherichia coli
serotype O111:B4 (0.1–0.5 mg/kg; Sigma Aldrich, St. Louis,
MO, USA). Blood glucose levels were measured 2, 4, 6 and 8 h
after the LPS injection using the glucose oxidation method (glu-
cose CII test; Wako, Osaka, Japan).
Pyruvate tolerance test
LPS from 0.1–0.5 mg/kg or saline (control) was given in a single
intraperitoneal injection to 16-h fasted rats weighing approxi-
mately 250 g. After 4 h, glucose levels were measured in blood
collected from the tail vein, and pyruvate (1 g/kg) was then
injected intraperitoneally into rats. Blood was serially collected
at 30-min intervals after the pyruvate injection. In NOS inhibi-
tor pretreatment experiments, rats were injected intravenously
with NG-monomethyl-L-arginine (L-NMMA; 10 mg/kg)
20 min before the intraperitoneal injection of LPS (0.5 mg/kg).
Preparation and incubation of hepatocytes and splenocytes
Hepatocytes were isolated from male Wistar rats fasted for
16 h by collagenase digestion as described previously13. Isolated
hepatocytes (>90% viable by the trypan blue exclusion test)
were seeded on 24-well plastic plates (Corning, New York, NY,
USA) at a density of 5.0 9 105 cells per well. Cells were cul-
tured in Krebs–Ringer buffer and incubated in 95% O2/5%
CO2 at 37°C for 2 h in the presence of 0.24 mmol/L 3-isobu-
tyl-1-methylxanthine and gluconeogenic precursors (10 mmol/L
lactate and 1 mmol/L pyruvate) with/without LPS (0.02-
20.0 lg/mL). After the incubation, medium was centrifuged at
50 g for 3 min to separate supernatants and pellets.
Splenocytes were harvested from the spleens of rats by
homogenization. Crude cells were left to sink to the bottom of
tubes for 1 min, and the supernatant was then centrifuged at
500 g for 3 min. Ammonium chloride was added to the precip-
itate in order to lyse red blood cells. Then, 30 s later, cells were
washed twice with Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM). Isolated splenocytes were seeded on 10-cm plastic
dishes at a density of 1.0 9 106 cells/mL, and cultured in
DMEM supplemented with 100 lmol/L 2-mercaptoethanol
with/without LPS (0.01–1.0 lg/mL).
Gluconeogenesis in perfused rat livers
Rat liver perfusion was carried out with the ﬂow-through
method, as described previously14. Details are shown in
Appendix S1.
Effects of LPS on nitrate + nitrite, TNF-a, IFN-c, IL-1b, IL-6 and
IL-10 production in splenocytes
The concentrations of the LPS-induced cytokines, NO, IFN-c,
IL-1b, IL-6 and IL-10 in the culture medium of splenocytes
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were measured after 4, 8, 16, and 24 h. NO is hydrolyzed in
medium, and this is followed by the formation of NO stable
metabolites (nitrate + nitrite [NOx]). NOx concentrations were
measured using the Griess method (NO2/NO3 Assay Kit-CII;
Dojindo, Kumamoto, Japan). Enzyme-linked immunosorbent
assay was carried out to measure the levels of TNF-a (IBL,
Gumma, Japan), IFN-c (R&D systems, Minneapolis, MN,
USA), IL-1b (R&D systems), IL-6 (Arigobio, Hsinchu, Taiwan)
and IL-10 (R&D systems).
Effects of inﬂammatory cytokines on hepatic gluconeogenesis
in vitro
Primary hepatocytes were prepared as described above, and cul-
tured with SNP, TNF-a, IFN-c, IL-1b, IL-6 and IL-10. SNP was
used as a NO donor. After a 2-h incubation, the concentration
of glucose in the supernatant was measured as described above.
Immunoblotting analysis
Western blotting was carried out as described previously with
slight modiﬁcations13. Details are shown in Appendix S2.
Co-culture of splenocytes and hepatocytes
Isolated splenocytes were seeded on a polycarbonate membrane
on the bottom of insert cups for 24-well plastic plates (Thermo
Fisher Scientiﬁc, Roskilde, Denmark) at a density of
3.0 9 106 cells/cup, and were cultured for 24 h in DMEM sup-
plemented with 100 lmol/L 2-mercaptoethanol with/without
LPS (1.0 lg/mL). Freshly isolated hepatocytes were then co-cul-
tured in 24-well plates with the above-described splenocytes for
an additional 2 h in DMEM supplemented with/without LPS
(1.0 lg/mL), without direct contact between splenocytes and
hepatocytes.
Total RNA extraction, complementary deoxyribonucleic acid
synthesis and real-time reverse transcription polymerase chain
reaction
Total RNA was extracted from hepatocytes using Sepazol
(Nacalai Tesque, Kyoto, Japan), and complementary deoxyri-
bonucleic acid synthesis was synthesized using the PrimeScript
RT reagent Kit (Takara Bio, Shiga, Japan). SYBR Premix Ex
Taq II (Takara Bio) was used for real-time polymerase chain
reaction. The rat sequences for forward and reverse primers to
detect PEPCK, G6Pase and b-actin as an inner control are
shown in Table S1. Polymerase chain reaction was carried out
with the Step One Plus Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) under the following condi-
tions: initial denaturation at 95°C for 10 s, followed by 40
cycles at 95°C for 5 s and 60°C for 34 s.
Effects of LPS on blood NOx concentrations
Blood NOx concentrations were measured, followed by an
intraperitoneal injection of saline (control) or LPS (0.1–0.5 mg/
kg). Blood was collected after 2, 4, 8 and 24 h, and the levels
of NOx produced were measured as described above. In NOS
inhibitor pretreatment experiments, rats were injected intra-
venously with L-NMMA (10 mg/kg) 220 min after the injec-
tion of LPS (0.5 mg/kg).
Statistical analysis
Comparisons between two groups were carried out using an
unpaired Student’s t-test. A one-way ANOVA followed by Dun-
nett’s post-hoc test was carried out for more than two groups.
A value of P < 0.05 was considered signiﬁcant.
RESULTS
Time-course of effects of LPS on blood glucose levels
As the ﬁrst step to elucidate the effects of LPS on glucose
homeostasis, we examined the time-course of changes in blood
glucose levels using rats. The intraperitoneal injection of LPS
(0.1–0.5 mg/kg) or saline (control) did not signiﬁcantly alter
blood glucose levels (Figure 1).
Effects of LPS on the pyruvate tolerance test
We next evaluated the effects of LPS on hepatic gluconeogene-
sis using the pyruvate tolerance test. Four hours after the injec-
tion of LPS or saline intraperitoneally, elevations in blood
glucose levels after the intraperitoneal administration of pyru-
vate were signiﬁcantly suppressed in the LPS groups (Figure 2).
This suppressive effect of LPS (0.5 mg/kg) on gluconeogenesis
was signiﬁcant 30 min (control, 6.3 – 0.49 mmol/L; LPS,
4.6 – 0.51 mmol/L, P < 0.05 vs control), 60 min (control,
6.1 – 0.49; LPS, 3.6 – 0.41 mmol/L, P < 0.01 vs control) and
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Figure 1 | No significant differences in blood glucose levels after an
injection of lipopolysaccharide (LPS) or saline. Blood glucose levels of
randomly fed Wistar rats were measured, followed by an injection of
saline (control) or LPS (0.1–0.5 mg/kg bodyweight) intraperitoneally.
Blood glucose levels were measured 2, 4, 6 and 8 h after the injection.
Rats were provided with food ad libitum, even after the LPS injection.
White circles, control; white triangles, LPS (0.1 mg/kg bodyweight); black
circles, LPS (0.5 mg/kg bodyweight). Values are means – standard error
(n = 5).
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P < 0.01 vs control) after the pyruvate injection. This suppres-
sive effect of LPS (0.1 mg/kg) was signiﬁcant 30 min (LPS,
4.2 – 0.48 mmol/L, P < 0.01 vs control) and 120 min (LPS,
4.3 – 0.47 mmol/L, P < 0.05 vs control) after the pyruvate
injection. Blood glucose levels after the intraperitoneal injection
of vehicle (saline), but without pyruvate injection were not sig-
niﬁcantly affected. These results show that LPS decreases gluco-
neogenesis from pyruvate.
Effects of LPS on gluconeogenesis in isolated hepatocytes
In order to investigate the direct effects of LPS on hepatocytes,
we examined gluconeogenesis using isolated hepatocytes. The
effects of LPS on glucose synthesis from 10 mmol/L lactate plus
1 mmol/L pyruvate in a 2-h incubation of hepatocytes with
LPS are shown in Figure 3. LPS did not exert suppressive
effects on hepatic gluconeogenesis in freshly isolated hepato-
cytes at concentrations ranging between 0.02 and 20.0 lg/mL.
Glucose production by hepatocytes was signiﬁcantly reduced by
approximately 85% and 40% in the absence of gluconeogenesis
precursors in incubation medium and in the presence of
5 mmol/L metformin, a representative inhibitor of gluconeoge-
nesis, respectively.
Effects of LPS on gluconeogenesis in perfused livers
The effects of LPS on gluconeogenesis from lactate were investi-
gated in perfused rat livers. Glucose output into the perfusate
was stabilized under 2 lmol/g/h. After the perfusate had been
changed from basic buffer to Krebs–Ringer buffer containing
2 mmol/L lactate from 15 to 105 min, glucose output rapidly
increased and reached a steady state at approximately 10 lmol/
g/h. After the washout of lactate, glucose output decreased to
2 lmol/g/h. An intraperitoneal injection of LPS (0.5 mg/kg)
4 h before liver perfusion did not signiﬁcantly change the glu-
cose output from that in the control (Figure 4a). In Figure 4b,
LPS (0.1–0.5 mg/kg/30 min) was infused continuously from 55
to 85 min with perfusion buffer, and had no signiﬁcant effect
on glucose output. Metformin (5 mmol/L) was infused continu-
ously from 55 to 85 min with perfusion buffer, and signiﬁ-
cantly suppressed glucose output. These results suggest that the
effects of LPS on glucose output in perfused rat livers were not
signiﬁcantly different from those in the controls.
Time-course of the production of cytokines induced by LPS in
splenocytes
As the suppressive effects of LPS on hepatic gluconeogenesis
might be due to its indirect effects on the liver, we examined
the production of cytokines in immunocytes with the addition
of LPS. The main cytokines, NO, TNF-a, IFN-c, IL-1b, IL-6
and IL-10, induced by LPS in splenocytes were measured. The
exposure of splenocytes to LPS signiﬁcantly increased the pro-
duction of NO, TNF-a, IFN-c, IL-1b and IL-10 in a concentra-
tion-dependent manner (Figure 5).
Figure 5 shows the time-course of increases in NOx, TNF-a,
IFN-c, IL-1b and IL-10 production after the application of LPS
at concentrations of 0.01–1.0 lg/mL. IL-6 was undetectable in
the absence and presence of LPS (0.01–1.0 lg/mL) at all sam-
























Figure 2 | Lipopolysaccharide (LPS) decreased gluconeogenesis from
pyruvate. LPS (0.1–0.5 mg/kg bodyweight) or saline (control) was
injected intraperitoneally to rats fasted for 16 h. After 4 h, blood
glucose levels were measured, and pyruvate (1 g/kg bodyweight) was
then injected intraperitoneally into the rats. Blood glucose levels during
the pyruvate tolerance test were measured at intervals of 30 min after
the pyruvate injection. White circles, control; white squares, negative
control without pyruvate injection; white triangles, LPS (0.1 mg/kg
bodyweight); black circles, LPS (0.5 mg/kg bodyweight). Values are
means – standard error (n = 5). *P < 0.05, **P < 0.01 significantly






























Figure 3 | No suppressive effects of lipopolysaccharide (LPS) on
gluconeogenesis in primary hepatocytes. Glucose production was
measured in primary hepatocytes treated with or without LPS (2 h
after exposure to LPS concentrations ranging between 0.02 and
20.0 μg/mL). White bar, negative control without gluconeogenesis
precursors (NC); black bar, LPS 0.02–20.0 μg/mL; right hatched bar,
positive control (PC); left hatched bar, 5 mmol/L metformin (Met).
Values are mean – standard error (n = 5). *P < 0.05, **P < 0.01 vs
positive control.
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Effects of cytokines on gluconeogenesis in hepatocytes
The effects of cytokines (NO, TNF-a, IFN-c, IL-1b, IL-6 and
IL-10), which are known to be induced by LPS, on gluconeogen-
esis in isolated hepatocytes were examined. After a 120-min incu-
bation with cytokines, glucose concentrations were measured in
order to investigate the effects of cytokines on gluconeogenesis in
hepatocytes (Figure 6). The inclusion of SNP in incubation med-
ium resulted in the inhibition of glucose synthesis without insu-
lin. This inhibition was signiﬁcant at concentrations >50 lmol/L
SNP (Figure 6a). TNF-a, IFN-c, IL-1b, IL-6 and IL-10 had no
signiﬁcant effects on gluconeogenesis in hepatocytes (Figure 6b–
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Figure 4 | No suppressive effects of lipopolysaccharide (LPS) on glucose output in perfused rat livers. (a) Four hours after the intraperitoneal
injection of LPS, livers were perfused with Krebs–Ringer buffer, and from 15 min to 105 min with 2 mmol/L lactate. White circles, control; black
circles, LPS. Values are mean – standard error (n = 4). (b) LPS or vehicle was not injected intraperitoneally, and livers were perfused with Krebs–
Ringer buffer. LPS (0.1 or 0.5 mg/kg bodyweight/30 min) or metformin (5 mmol/L) was administered in perfusion buffer from 55 min to 85 min.
White circles, control; black circles, LPS (0.5 mg/kg bodyweight/30 min); white triangles, LPS (0.1 mg/kg bodyweight/30 min); black triangles,
metformin (5 mmol/L). Values are mean – standard error (n = 4). *P < 0.05, **P < 0.01 vs control.
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of gluconeogenesis precursors in incubation medium or in the
presence of 5 mmol/L metformin. These results show that LPS-
induced NO is a key regulator of hepatic gluconeogenesis.
Effects of NO on adenosine monophosphate-activated protein
kinase-a phosphorylation in hepatocytes
In order to investigate the underlying mechanisms by which
NO suppresses gluconeogenesis, we examined the effects of NO
and metformin on adenosine monophosphate-activated protein
kinase-a (AMPKa) using isolated hepatocytes. The therapeutic
effects of metformin are mediated by the activation of AMPK,
leading to a decrease in hepatic gluconeogenesis. After a 2-h
exposure, 50 lmol/L SNP and 5 mmol/L metformin stimulated
the phosphorylation of Thr172 of AMPKa, suggesting the acti-
vation of AMPK (Figure 7).
Effects of LPS on co-cultured splenocytes and hepatocytes
The interaction between splenocytes and hepatocytes in response
to LPS was investigated in vitro. After splenocytes and hepato-
cytes were co-cultured for 2 h in culture medium with/without
LPS (1.0 lg/mL), the mRNA expression levels of PEPCK and
G6Pase, master regulators of glucose production, were examined
in hepatocytes. G6Pase mRNA expression levels were signiﬁ-
cantly lower in LPS-treated hepatocytes than in LPS-untreated
hepatocytes, whereas those of PEPCK were lower in LPS-treated
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Figure 5 | Time-courses of the production of cytokines by splenocytes exposed to various concentrations of lipopolysaccharide (LPS). The
concentrations of the LPS-induced cytokines, (a) nitrate + nitrite (NOx), (b) tumor necrosis factor-a (TNF-a), (c) interferon-c (IFN-c), (d) interleukin (IL)-
1b, and (e) IL-10 in the culture medium of splenocytes were measured after 4, 8, 16 and 24 h. White bar, control; right hatched bar, LPS (0.01 μg/
mL); black bar, LPS (0.1 μg/mL); left hatched bar, LPS (1.0 μg/mL). Values are mean – standard error (n = 6). *P < 0.05, **P < 0.01 significantly
different from the corresponding control.
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Time-course of blood NOx concentrations after the LPS
injection
In order to investigate the in vivo effects of LPS on NO pro-
duction, we examined the time-course of blood NOx concen-
trations after the LPS injection using rats. Blood NOx
concentrations were signiﬁcantly higher in the LPS group
(0.5 mg/kg) than in the control group from 4 h to 24 h (Fig-
ure 9). NOx concentrations were slightly higher in the LPS
group (0.1 mg/kg) than in the control group. NOx concentra-
tions at 4 h were signiﬁcantly lower in the presence of
L-NMMA (10 mg/kg), which was intravenously injected
220 min after LPS (0.5 mg/kg i.p.), than in its absence. These
results show that LPS signiﬁcantly increased the in vivo produc-
tion of NO, which could suppress hepatic gluconeogenesis.
Inhibitory effects of L-NMMA on LPS action in the pyruvate
tolerance test
In the pyruvate tolerance test, the pretreatment of L-NMMA
(10 mg/kg i.v.) signiﬁcantly reduced the inhibitory effects of
LPS (0.5 mg/kg i.p.) on gluconeogenesis 60 min after the pyru-
vate injection (pretreatment, 5.5 – 0.23 mmol/L; no pretreat-
ment, 3.6 – 0.41 mmol/L, P < 0.05 vs pretreatment).
DISCUSSION
The results of the present study showed that LPS, a substance
that produces endotoxic shock, decreased gluconeogenesis from
pyruvate in vivo. We also showed that the LPS injection
increased the plasma levels of TNF-a and IFN-c, which are
inﬂammatory cytokines. A previous study reported that TNF-a
prevented enhancements in glucagon-stimulated gluconeogene-
sis from lactate in isolated hepatocytes9. In that study, hepato-
cytes were pre-incubated for 4 h in culture medium containing
fetal calf serum and insulin. Hepatocytes were then cultured for
44 h in the absence of fetal calf serum, and stimulated with
glucagon for an additional 4 h in medium M199 supplemented
with TNF-a and [14C]lactate. The rate of gluconeogenesis was
then assessed radiochemically. However, another study reported
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Figure 6 | Sodium nitroprusside (SNP) reduced glucose production in hepatocytes. Primary hepatocytes isolated from rats were incubated with
various concentrations of (a) SNP, (b) tumor necrosis factor-a (TNF-a), c) interferon-c (IFN-c), (d) interleukin (IL)-1b, (e) IL-6 and (f) IL-10 for 2 h.
White bar, negative control without gluconeogenesis precursors (NC); black bar, various concentrations of cytokines; right hatched bar, positive
control (PC); left hatched bar, 5 mmol/L metformin (Met). Values are mean – standard error (n = 5). *P < 0.05, **P < 0.01 vs positive control.
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glucagon levels in vivo15. In that study, rats were injected
intraperitoneally with TNF-a, followed by collagenase digestion
of the liver to isolate hepatocytes. Isolated hepatocytes were incu-
bated for 2 h in culture medium containing alanine as a gluco-
genic amino acid, and the rate of hepatic gluconeogenesis was
measured. The present results showed that TNF-a failed to affect
gluconeogenesis in freshly isolated hepatocytes. In the present
study, isolated hepatocytes were incubated for 2 h in Kreb–
Ringer buffer with gluconeogenic precursors (lactate and pyru-
vate) in the presence of TNF-a. The reasons for the discrepancy
between the present results and the ﬁndings of Christ et al. and
Blumberg et al. remain unknown, but might be attributed to dif-
ferences in experimental protocols and conditions.
Regarding IFN-c, Wang et al.16 reported that a deﬁciency in
IFN-c reduced hepatic G6Pase activity and enhanced glucose
tolerance in mice. In that study, the bodyweight of and food
intake by IFN-c knockout mice were lower, whereas their phys-
ical activity was greater than the control. Nevertheless, the pre-
sent results showed that the addition of IFN-c to culture
medium did not affect gluconeogenesis in isolated rat hepato-
cytes. The reason for the discrepancy in our results and the
ﬁndings of Wang et al. remains unclear, but again might be
ascribed to differences in the methods and species used.
Chronic inﬂammatory signaling is generally regarded as a
key cause of insulin resistance17,18. We herein showed that the
acute exposure of hepatocytes to TNF-a and IFN-c did not
have any effects on gluconeogenesis. Therefore, the acute and
chronic effects of inﬂammatory cytokines appear to differ.
iNOS, known as an LPS-stimulated protein, has beneﬁcial
roles in host immunity19. iNOS mutant mice have an increased
susceptibility to infection, showing the importance of iNOS in
host defenses against infectious disease20,21. Excessive amounts
of NO produced by iNOS might react with the superoxide
anion to generate the peroxynitrite radical, which has detrimen-
tal effects on cells22. Regarding glucose metabolism, iNOS was
shown to reduce glucose tolerance and increase insulin resis-
tance11,23. Conversely, in septic shock, the genetic deletion of
iNOS in mice maintained hepatic gluconeogenesis, leading to
the prevention of hypoglycemia24. Therefore, the impact of
iNOS on glucose metabolism remains controversial.
The disruption of endothelial NOS causes insulin resis-


























Figure 7 | Sodium nitroprusside (SNP) stimulated adenosine
monophosphate-activated protein kinase-a (AMPKa) phosphorylation
(p-AMPKa) in hepatocytes isolated from rats. After 2-h exposure,
AMPKa phosphorylation was significantly stimulated by 50 μmol/L SNP
or 5 mmol/L metformin (Met). White bar, control; black bar, 50 μmol/L
SNP; left hatched bar, 5 mmol/L Met. Values are mean – standard error










































Figure 8 | Lipopolysaccharide (LPS) suppressed messenger ribonucleic
acid (mRNA) expression levels of gluconeogenesis in hepatocytes co-
cultured with splenocytes. After splenocytes and hepatocytes were co-
cultured for 2 h in culture medium with/without LPS (1.0 μg/mL), the
mRNA expression levels of (a) phosphoenolpyruvate carboxykinase
(PEPCK) and (b) G6Pase were examined in hepatocytes. The mRNA
expression levels of G6Pase were significantly lower in LPS-treated
hepatocytes than in LPS-untreated hepatocytes, whereas those of
PEPCK were lower in LPS-treated hepatocytes than in LPS-untreated
hepatocytes. White bar, control; black bar, LPS (1.0 μg/mL). Values are
mean – SE (n = 5). *P < 0.05 vs the control.
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diabetic mice26. Therefore, endothelial NOS is currently attract-
ing attention for its central role in the regulation of glucose
metabolism. The production of an appropriate amount of NO
might be important in the regulation of glucose metabolism
and prevention of infection in patients with diabetes.
Endotoxic hypoglycemia has been reported in patients with
liver cirrhosis and kidney failure27,28, implying that a dysfunction
in gluconeogenic organs is associated with septic hypoglycemia.
In the present study, after the LPS injection, gluconeogenesis
from pyruvate in vivo decreased in the pyruvate tolerance test.
Blood NOx concentrations also signiﬁcantly increased 4 h after
the LPS injection. Regarding our study in vitro, SNP suppressed
gluconeogenesis in isolated hepatocytes, whereas LPS stimulated
the production of NOx in isolated splenocytes. In co-cultures
of splenocytes and hepatocytes, LPS suppressed G6Pase mRNA
expression in hepatocytes. Collectively, these results suggest that
NO produced by splenocytes is involved in hypoglycemia with
endotoxic shock. LaNoue et al.4 reported that the intraperi-
toneal administration of LPS to rats reduced G6Pase activity,
which is consistent with the present study.
Regarding the LPS dosage applied in in vivo experiments,
Raetzsch et al.29 reported that the intraperitoneal application of
LPS at dosages of 0.05–0.5 mg/kg reduced blood glucose levels
in a dose-dependent manner, with the maximal response being
observed at 0.5 mg/kg. In that study, the intraperitoneal appli-
cation of LPS (5 mg/kg) was lethal. Consistent with their study,
we used LPS dosages of 0.1–0.5 mg/kg to examine the effects
of LPS on glycemia and the pyruvate tolerance test.
The spleen is a lymphatic organ that is located in the left
hypochondriac region. Blood in this organ is rich in macro-
phages. The splenic vein directly connects to the portal vein.
LPS is known to induce splenomegaly, which is associated with
a larger number of immune cells than that in a healthy spleen.
Thus, in endotoxin shock, NO produced by splenocytes is more
likely to play an important role in the inhibition of hepatic glu-
coneogenesis.
The limitations of the present study need to be considered.
In this study, we did not carry out experiments using a co-cul-
ture of hepatocytes and Kupffer cells, which have been shown
to release NO by various stimuli including LPS30,31. NO pro-
duced by Kupffer cells in response to LPS might inhibit hepatic
gluconeogenesis. Further research is warranted. Another limita-
tion is that we carried out liver perfusion using the ﬂow-
through method, not the re-circulation method. In our perfu-
sion method, some of the NO produced by Kupffer cells in
response to LPS might have been washed out by fresh perfu-
sion solution, thereby decreasing its effects on hepatocytes.
Goto et al.32 carried out liver perfusion using the re-circulation
method in 10-day-old rats, and reported that the intraperitoneal
pretreatment of LPS reduced hepatic gluconeogenesis. The rea-
sons for the discrepancy between the present results and the
ﬁndings of Goto et al. remain unknown, but might be attribu-
ted to differences in the experimental protocols used. In the
present study, the suppression of glucose output was not
observed in the liver perfusion experiment with LPS. Therefore,
further studies are required.
Decreased NO levels in blood have been reported with diabetes
in humans33 and rats34. The regulation of NOS-mediated NO sig-
naling might open a new avenue for the treatments for diabetes.
In conclusion, high blood concentrations of NO in endotox-
emia might cause hypoglycemia through the inhibition of hep-
atic gluconeogenesis in an insulin-independent pathway. The
regulation of iNOS-mediated NO signaling could lead to new
treatments for hypoglycemia in endotoxemia.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Appendix S1 | Gluconeogenesis in perfused rat livers.
Appendix S2 | Immunoblotting analysis.
Table S1 | Primer sequences used in quantitative reverse transcription polymerase chain reaction
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